Created at 5:13 p.m. Oct, 09, 2025
Author: Caleb_Meadows
Related Note: 1485037189108 4
Rationale for change

Amboss lists using SSRIs or SNRIs in general and not venlafaxine specifically. Updated to provide the examples in the extra field of agents amboss provided as examples.
Source: AMBOSS - https://next.amboss.com/us/article/-80D63?utm_source=navbar&utm_medium=anki&utm_campaign=anki&utm_term=ptsd&guid=qo%252CwEGs%253F%25219&aid=12b9157f-d56c-49c3-9a37-0a1030bd0668&uid=xUOVE27u0#Z2b5a77ee2051fee6724ad813948b6748

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Empty field
Additional Resources
Empty field
One by one
Empty field
#AK_Step2_v12::#Bootcamp::Psychiatry::01_Diagnosis_and_Management::01_Mood_Disorders::05_SSRIs_and_SNRIs #AK_Step1_v12::#UWorld::COMLEX::25732 #AK_Step2_v12::Original_decks::Dorian::psych::fapsych::pharm #AK_Step2_v12::#Resources_by_rotation::Psych::fapsych::pharm #AK_Step3_v12::#UWorld::12600 #AK_Step1_v12::#Pixorize::03_Pharmacology::17_Psych_Pharm::04_SSRIs #AK_Step1_v12::^Systems::Neuro::Pharmacology #AK_Step2_v12::!Shelf::Psych::no_dupes #AK_Step2_v12::#Resources_by_rotation::FM::ome::psych::pharm #AK_Step1_v12::#Bootcamp::Psychiatry::09_Pharmacology::01_SSRIs #AK_Step1_v12::#SketchyPharm::06_Neuro_&_Psych::02_Antidepressants_&_Anxiolytics::01_SSRIs,_SNRIs,_Cyproheptadine #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::07_Selective_serotonin_reuptake_inhibitors #AK_Step2_v12::!Shelf::FM::no_dupes #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::20_SNRIs #AK_Step1_v12::#Pixorize::03_Pharmacology::17_Psych_Pharm::New::10_SSRIs #AK_Step2_v12::#SketchyPsych::09_Trauma_Disorders::01_Stress_Disorders::01_Acute_Stress_Disorder_&_PTSD #AK_Step2_v12::#OME::04_Psychiatry::04_PTSD #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::19_SSRIs #AK_Step1_v12::#UWorld::Step::11846 #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::08_Serotonin-norepinephrine_reuptake_inhibitors #AK_Step2_v12::#AMBOSS::NH0-qh #AK_Step2_v12::Original_decks::Dorian::fam::ome::psych::pharm #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step2_v12::#OME::04_Psychiatry::15_Psych_Pharm_2 #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step2_v12::#UWorld::COMLEX::102091 #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#OME::Clinical::Psychiatry::Mostly_Mood::Post-Traumatic_Stress_Disorders #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::06_Antidepressants::*Preferred_Medications_For_Selected_Psychiatric_Conditions #AK_Other::Only_Step_1&2_Overlap #AK_Step2_v12::#UWorld::Step::11937 #AK_Step2_v12::#UWorld::Step::12186 #AK_Step2_v12::#AMBOSS::Eta82m